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Abstract
Background: Feline immunodeficiency virus (FIV) is a lentivirus of cats that establishes a lifelong persistent
infection with immunologic impairment.
Results: In an approximately 2 year-long experimental infection study, cats infected with a biological isolate of FIV
clade C demonstrated undetectable plasma viral loads from 10 months post-infection onward. Viral DNA was
detected in CD4+CD25+ and CD4+CD25- T cells isolated from infected cats whereas viral RNA was not detected at
multiple time points during the early chronic phase of infection. Viral transcription could be reactivated in latently
infected CD4+ T cells ex vivo as demonstrated by detectable FIV gag RNA and 2-long terminal repeat (LTR) circle
junctions. Viral LTR and gag sequences amplified from peripheral blood mononuclear cells during early and chronic
stages of infection demonstrated minimal to no viral sequence variation.
Conclusions: Collectively, these findings are consistent with FIV latency in peripheral blood CD4+ T cells isolated
from chronically infected cats. The ability to isolate latently FIV-infected CD4+ T lymphocytes from FIV-infected cats
provides a platform for the study of in vivo mechanisms of lentiviral latency.
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Background
Feline immunodeficiency virus (FIV) infection of cats is
an important animal model of human immunodeficiency
virus-1 (HIV-1) pathogenesis [1-3]. These two viruses
are phylogenetically related [4], and both infect naïve
and activated CD4+ T cell subsets as well as monocytes
in the susceptible host [2,5,6]. FIV-infected cats develop
an acute infection syndrome followed by a prolonged
asymptomatic period during which the CD4/CD8 T cell
ratio is inverted [5,7]. The asymptomatic phase of infec-
tion is generally followed by a terminal immunodefi-
ciency phase of disease termed feline acquired
immunodeficiency syndrome (FAIDS), akin to AIDS
[7-9].
Latently infected resting CD4+ T cells are the best
characterized reservoir for HIV-1 [10]. Such cells are
viral DNA-positive and viral RNA-negative and are
therefore effectively invisible to pharmacologic therapy
and immunological surveillance. The maintenance of
latent HIV infection in resting T cells of patients on
anti-retroviral therapy (ART) is of serious concern
because these cells remain a potential source of virus
reactivation [11-13]. Persistence of latently infected
memory CD4+ T cells, and potentially other cell types
permissive for virus (e.g. macrophages), precludes their
elimination by ART or the host immune system for the
lifetime of the patient [14] and remains a principal bar-
rier to the long-term pharmacologic and immunologic
eradication of lentiviral infections [11,15-18].
For HIV-infected people, there is ample evidence that
latently infected reservoirs of CD4+ T cells are estab-
lished very early on during lentiviral infection, in many
cases, prior to the institution of ART [19-26]. Studies
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million resting CD4+T cells from HIV patients on
ART harbor latent provirus [10,27]. The study of
HIV-1 latency in vivo has therefore been hampered by
the scarcity of latently-infected cells and restricted
access to lymphoid tissues from HIV-infected patients
[17,28]. Current models of HIV latency include SIV-
infected non-human primates, HIV-infected huma-
nized mice, and a variety of in vitro models utilizing
either cell lines or primary cells [29]. Although each
of these latency models has both advantages and dis-
advantages, individually each model fails to fully cap-
ture the complex properties of HIV latency [29].
Advantages of the primate model include the ability
to study multiple different organ systems concurrently
and an immune response which resembles a human
immune response. Disadvantages of this model
include the cost and a “contracted latency phase”
relative to HIV-infected humans. Advantages of the
mouse model include the ability to model thymic
infection and to study infected naïve cells. However,
the ability to study specific anatomical sites of infec-
t i o n ,s u c ha sg u tm u c o s a ,i sl i m i t e d ;a n dm e m o r yc e l l
infection is more difficult to explore in this model.
An additional in vivo mammalian model of lentiviral
latency would complement latency models currently
available. The FIV-infected cat is the only naturally
occurring model of lentivirus-induced immunodefi-
ciency. The latency phase of the FIV-infected cat is
prolonged and more accurately reflects the time
frame of HIV-infected humans prior to the onset of
immunodeficiency [30]. The cat’s mucosal tissues and
immunologic/hematopoietic tissues can be serially
and invasively biopsied for evidence of host pathology
and virologic changes. Finally, a wide range of immu-
nologic reagents now exists for studying the feline
immune system.
This report presents a long-term comprehensive study
that defines virologic parameters of FIV infection in iso-
lated peripheral blood leukocytes during the asympto-
matic phase and, more broadly, positions the
experimentally FIV-infected cat as an animal model of
lentiviral cellular latency. Accordingly, viral RNA and
DNA was assayed in peripheral blood mononuclear cells
(PBMCs), monocytes, CD4+CD25+ (activated/regula-
tory) and CD4+CD25- (resting) lymphocytes from cats
experimentally infected with FIV over an approximately
two year observation period. Critical observations
revealed persistently detectable viral DNA in all exam-
ined cell types whereas viral RNA was not detected in
CD4+CD25+ and CD4+CD25- lymphocytes, consistent
with the concept of peripheral CD4+ T cell lentiviral
latency.
Results
FIV infection of cats induced transient lymphadenopathy
and alterations in T cell subsets
Four FIV specific pathogen-free (SPF) kittens were
inoculated with FIV clade C isolate, FIV-C-Pgmr [31], to
assess virus localization and expression over a prolonged
time period while two SPF kittens served as mock-
infected controls. All inoculated cats seroconverted to
FIV by one month post-infection (PI). Mock-infected
cats remained seronegative for FIV throughout the
study. All FIV-inoculated cats demonstrated bilateral
popliteal lymphadenopathy, whereas other peripheral
lymph nodes were not affected. Lymphadenopathy man-
ifested as early as three days PI, was generally main-
tained for approximately 10 months, and was not
detected in mock-inoculated control cats. A single cat
(165) exhibited periodic, recurrent suppurative parony-
chia and dorsal cervical/auricular/chin dermatitis. Multi-
ple bacterial and fungal cultures were negative for fungi
and intermittently positive for Streptococcus canis and
Escherichia coli. These inflammatory lesions emerged at
5-12 months PI and were managed with appropriate
topical and oral antibiotic treatments.
The CD4/CD8 T cell ratio for each FIV-infected and
uninfected control cat was plotted as a function of time
in Figure 1a. Although ratios were variable for both
groups of cats, these data suggested that FIV infection
resulted in a decrease in the CD4+ T cell subset in
blood. Furthermore, the mean value (0.925 +/- 0.567)
for cumulative CD4/CD8 T cell ratios from 2 to 112
weeks post infection for FIV-infected cats was signifi-
cantly less than that for the FIV-uninfected cats (1.8113
+/- 0.412; p < .0001; Figure 1b). Similarly, the cumula-
tive mean value for absolute CD4+ T cell counts in
blood (1556/μl blood +/- 1036) for infected cats was
lower compared to that measured for uninfected con-
trols (2490/μl +/- 1209, p = .0017; Figure 1c). In con-
trast, the cumulative mean value (2095/μl +/- 752) for
blood CD8+ T cell counts was greater for infected cats
compared to uninfected cats (1423/μl +/- 875, p =
.0017; Figure 1c).
FIV infection resulted in a transient plasma viremia
Plasma viral RNA (vRNA) quantification by a real-time
reverse transcription (RT)-PCR assay revealed a peak
viremia at 2 weeks PI that ranged from 4.9 × 10
4 to 5.8
×1 0
6 copies vRNA/ml of plasma (Figure 1d). Plasma
viremia was variably detectable from 2-44 weeks PI.
From 44 up to 98 weeks PI, plasma vRNA was not
detectable within the limits of the same real-time PCR
assay for all FIV-infected cats. The threshold of detec-
tion for the vRNA assay was approximately 80 copies
vRNA per ml of plasma. Mock-infected control cats
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(data not shown).
For the examined cell types, viral RNA expression was
restricted to monocytes in peripheral blood
To examine the question of persistent latent FIV infec-
tion of specific reservoir cell populations in the host,
assessment of cell-associated FIV viral DNA (vDNA)
and viral RNA (vRNA) for different cellular subsets was
critical, particularly in parallel with assay of plasma for
detectable vRNA. Therefore, standard methodology
involving IgG-coated magnetic beads, a fluorescence-
activated cell sorter, and monoclonal antibodies, either
specific or cross-reactive for feline cell surface markers,
was used to purify CD4+ T cells and monocytes from
PBMCs. CD4+ T cells were further purified for subsets
that were either CD25+ or CD25- to distinguish acti-
vated from resting cells respectively. Mean cell numbers
isolated for each subset were 1.8 × 10
7,3 . 6×1 0
5,5 . 5×
10
4 and 1.5 × 10
6, for PBMCs, monocytes, CD4+CD25+
and CD4+CD25- cells, respectively. Purified populations
of CD4+CD25+, CD4+CD25-, monocytes, and PBMCs
were next assayed for both viral DNA and RNA loads
using real-time PCR assays.
Viral DNA was detected in PBMCs from all FIV-
infected cats at all time points after virus inoculation
weeks post-inoculation
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Figure 1 Persistently inverted CD4/CD8 ratio despite undetectable plasma viral RNA. The CD4/CD8 T cell ratio for each FIV-infected and
uninfected control cat is plotted as a function of time (a). Cumulative data from each of the 2 uninfected control cats are plotted as thick grey
lines while data from the 4 individual FIV-infected cats are plotted as solid black lines (165), medium-dashed lines (184), short-dashed lines (186)
and dotted lines (187). The cumulative mean CD4/CD8 T-cell ratio for FIV-infected cats (black bar) was derived from all individual CD4/CD8 T-cell
ratios obtained from 2 weeks to 112 weeks PI and compared to the ratio for the mock-infected control cats (grey bar). Significance is shown
using p value with * p = .0001 (b). Cumulative means for the absolute number of CD4+ and CD8+ T cells for FIV-infected cats were compared
to values for uninfected control cats. Statistical significance is marked by an asterisk (*) and for this analysis p = .0017. Error bars denote standard
deviation (c). Plasma viral RNA copy numbers based on a FIV gag-based real-time PCR assay are plotted for each FIV-infected cat: circle (cat 165),
diamond (184), square (187) and triangle (186) (d). Assay detection threshold is approximately 80 copies viral RNA per ml.
Murphy et al. Retrovirology 2012, 9:12
http://www.retrovirology.com/content/9/1/12
Page 3 of 17(Figure 2a). DNA copy number ranged from 10 to 9.0 ×
10
4 copies/5 × 10
5 cells. Viral RNA was intermittently
detected in PBMCs of all four FIV-infected cats and
ranged from 10 to 9 x10
5 copies/10
6 copies GAPDH
(Figure 2a). The reason for this dramatic shift in vRNA
copy number has not been determined but does not
seem to be reflected in the clinical health of the cats at
that time. In general, gag vRNA varies by no more than
2-3 logs from one sample collection time point to the
next (generally set 10 weeks apart). Viral DNA (vDNA)
was detected in freshly isolated feline monocytes
obtained from all FIV-infected cats at all time points PI
(Figure 2b) and ranged from 67 to 8.6 × 10
4 copies/5 ×
10
5 cells. Viral RNA was sporadically detected in mono-
cytes derived from all four cats and ranged from 10
2 to
4.6 x10
4 copies/10
6 copies GAPDH. Viral DNA was also
detected in both CD4+CD25- and CD4+CD25+ lympho-
cytes isolated from all FIV-infected cats at all time
points after inoculation and ranged from 33 to 5.4 × 10
4
copies/5 × 10
5 cells or 10 to 1.5 × 10
4/5 × 10
5 cells (Fig-
ure 2c and 2d, respectively). Importantly, vRNA was not
detected in CD4+CD25- or CD4+CD25+ T cells isolated
from FIV-infected cats for any time points tested,
although early acute infection time points prior to 20
weeks PI were not tested. These findings revealed a
highly restricted pattern of vRNA expression that was
s u g g e s t i v eo fF I Vl a t e n c yi nt h e s ev D N A - p o s i t i v eC D 4 +
T cell subsets during early chronic infection. Viral DNA
and vRNA were not detected in PBMCs or any cell pre-
parations isolated from uninfected control cats (data not
shown). The threshold of detection was calculated to be
approximately 10 copies of FIV gag per 5 × 10
5 cells.
Episomal circular LTR DNA was not detected by standard
PCR assays in PBMCs or purified T cell subsets during
chronic infection
In addition to the linear DNA intermediates formed
during the reverse transcription step, two circular forms
of viral DNA have been identified in retrovirus-infected
cells [32] and are characteristic of a productive viral
infection while generally not present in latently infected
cells [33]. To further investigate the replication status of
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Figure 2 CD4+ T cells persistently infected in the absence of detectable plasma viral RNA. PBMCs (a), monocytes (b), CD4+CD25- T cells
(c), and CD4+CD25+ T cells (d) isolated from blood from all FIV-infected cats were examined over time PI for viral DNA and vRNA by real-time
PCR assays as described in Methods. Data from individual FIV-infected cats are plotted as solid black lines (165), medium-dashed lines (187),
short-dashed lines (186) and dotted lines (184).
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were designed to amplify and detect FIV-C-Pgmr circu-
lar episomal DNA products with either a single or dou-
ble LTR junction (circle junction, CJ). Progressively
fainter CJ PCR amplicons (CJ primer set A) were
detected in freshly isolated PBMCs from cats 184, 186
and 187 at 4, 6 and 9 weeks PI (Figure 3a). However, by
14 weeks PI, CJ episomal DNA was no longer detected
in PMBC. PBMCs isolated from a FIV-infected cat at six
weeks PI and cultured in vitro for six days served as a
positive control revealing both single and double LTR
CJ PCR products (Figure 3a). DNAs isolated from
monocytes, CD4+CD25+ lymphocytes and CD4+CD25-
lymphocytes purified from four different FIV-infected
cats from time points extending from 20 to 83 weeks PI
were also examined. No CJ PCR products (CJ primer set
A) were detected for any sample tested although all
samples were positive for 18s rRNA gDNA (data not
shown). These results are consistent with a detectable,
productive viral infection in PBMCs during acute
infection that becomes undetectable during the transi-
tion into early chronic infection at 14 weeks PI.
Ex vivo cultivation of PBMCs harvested from cats during
chronic FIV infection results in transcriptional activation
and production of infectious virus
At 50 and 134 weeks PI, blood was harvested from FIV-
C-Pgmr-infected and uninfected cats to determine infec-
tivity of FIV proviruses detected in PBMCs. Genomic
DNA preparations from freshly isolated PBMCs were
tested for FIV gag sequences using real-time PCR. FIV
gag PCR amplicons were detected in cells isolated from
all FIV-infected cats. For the 50 week PI samples, CJ
PCR analysis (CJ primer set B) performed on the same
DNA samples failed to detect appropriately-sized ampli-
cons by standard PCR assay. Viral gag RNA was not
detected by real-time RT-PCR for the same freshly iso-
lated PBMCs harvested from FIV-infected cats (data not
shown). To determine if detectable FIV DNA was cap-
able of producing replication competent virus particles,
1   2    3   4   5   6   7   8   9   10   11 12  13 14 
1000  
2000 
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a,b 
a  b 
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(+)    (-) 
MWM  MWM 
Figure 3 Analysis of viral circle junctions in cells isolated from chronically infected cats. Genomic DNA purified from freshly isolated PBMC
samples prepared from FIV-infected cats up to 14 weeks PI were tested for viral episomal circular LTR DNA by standard PCR assays (CJ primer set
A) designed to detect circular forms of vDNA (a). Circle junction PCR amplicons representative of either single LTR (arrow) or double LTR circles
(arrowhead) were generated from in vitro FIV-infected feline PBMCs (lane 1; positive control) and were absent in the negative control using a
water template (lane 2). Circle junction PCR reactions with expected PCR amplicons of 1423 bp (single LTR, arrow) and faint 1820 bp (double
LTR, arrowhead) are shown for PBMCs from cats 184, 186 and 187 sampled at 4 wks PI (lanes 3, 4 and 5); 6 wks PI (lanes 6, 7 and 8); 9 wks PI
(lanes 9, 10, 11); and 14 wks PI (lanes 12, 13 and 14), respectively. PCR products from standard PCR reactions for 18s rRNA (b) from samples in
the same corresponding lanes in (a), reveal positive, appropriately sized bands (~140 bp) except for lane 2 (water template negative control).
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at 50 weeks PI were also cultured ex vivo in PBMC
media supplemented with mitogens concanavalin A
(Con A) and phorbol myristate acetate (PMA) for 3
days followed by passage in PBMC culture media for 7
additional days as previously described [34]. Genomic
DNA samples prepared from ex vivo-cultured cells (har-
vested at 10 days post-cultivation) were subsequently
shown to be positive for single (500 bp) and double
(faint 800 bp) CJ LTR DNA amplicons (CJ primer set B,
Figure 4a) for all four FIV-infected cats while samples
from an uninfected control cat were negative (Figure
4b). Although the double CJ LTR amplicon is faint, the
lack of a single CJ LTR amplicon in the negative control
lane suggests that it lacks a double as well (the single
LTR circle amplicon seems to be a favored end-product
of the polymerase chain reaction relative to the double
LTR as a result of its shorter amplicon size). Further-
more, viral RNA was detected by real-time PCR in
supernatants harvested from PBMC cultures, whereas
cultures from uninfected control cats were negative for
viral RNA (data not shown).
To assess infectivity of ex vivo generated virions, clari-
fied PBMC culture supernatants were inoculated onto
PBMCs freshly isolated from uninfected SPF cats. At 7
days post-cultivation, whole cell DNA and RNA were
isolated from cultured PBMCs, and RNA isolated from
culture supernatants were positive for viral gag
sequences for three of the four FIV-infected cats (184,
165 and 186) when assayed by real-time PCR. Samples
derived from an uninfected control cat (185) were nega-
tive for viral nucleic acid as expected. These data indi-
cate that ex vivo activation of viral RNA-negative
PBMCs from FIV-infected cats results in the production
of infectious virions.
Primers designed to amplify LTR CJ located outside
of the LTR (i.e. within gag and env) can utilize linear
DNA molecules as substrates, yielding spurious CJ pro-
ducts indistinguishable from genuine CJ amplicons
[35]. This process is thought to occur first through lin-
ear amplification of the LTR followed by LTR hybridi-
zation with subsequent exponential amplification. It is
possible, however, to design forward and reverse pri-
mers complementary to the U5 and U3 sequences,
amplify across the unique LTR-LTR junction and spe-
c i f i c a l l ya m p l i f y2 - L T RC J( F i g u r e4 b ) .T h e r e f o r e ,w e
designed a real-time PCR assay utilizing 2-LTR CJ
primers (FIVU5 for and FIVU3 rev,C Jp r i m e rs e tC ,
Table 1). Each real-time PCR assay was run in tripli-
cate followed by a melt curve to assess amplicon valid-
ity. Following PCR, agarose gel electrophoresis was
performed to assess amplicon size. Two LTR CJ pri-
mers (CJ primer set C, Figure 5a) were utilized in a
PCR reaction with PBMCs isolated from all four FIV-
infected cats and one uninfected cat (185).
DNA samples derived from PBMCs harvested at 9, 28,
40 weeks PI (184), 78 weeks PI (184, 186, 187), 90 and
102 weeks PI (165) were all positive for real-time 2-LTR
CJ amplicons. Samples derived from PBMCs harvested
at 122 weeks PI (186) and 134 weeks PI (165) were
negative for real-time 2-LTR CJ amplicons. In order to
assess the validity of the 2-LTR CJ PCR amplicons, sam-
ples were cloned from ex vivo-cultured PBMCs har-
vested from two FIV-infected cats. PBMCs were isolated
from FIV- infected cats at 6 weeks (184) and 12 weeks
(165) PI and cultured ex vivo for 3 to 6 days. DNA was
isolated from ex vivo-cultured cells, 2-LTR CJ PCR was
performed (CJ primer set C), and PCR amplicons were
cloned and sequenced (Figure 5b). All of the sequenced
samples demonstrated intact U5 regions with variable
b 
1  2   3  4  5 
 1  2  3  4  5  
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500 
300 
env  gag 
c 
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a  b 
U3   R  U5     U3  R   U5 
U3  R   U5 
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MWM 
Figure 4 In vitro viral rescue assay in PBMC. Schematic diagrams
of circle junction PCR utilizing primers outside the LTR, circle
junction primer sets A and B (a) Primers are indicated by triangles.
PBMCs were isolated at 50 weeks PI from both FIV-infected and
uninfected control cats and cultured ex vivo for 10 days followed by
PCR amplification for LTR circle junction sequences (CJ primer set B)
(b). Expected PCR amplicons of 500 bp (single LTR, arrow) and faint
800 bp (double LTR, arrowhead) are present. Circle junction PCR
products generated from cultured PBMCs from cats 184, 185 (FIV
negative, negative control), 186, 187 and 165 are represented by
lanes 1-5, respectively. PCR products were generated for 18s
ribosomal RNA gene (d) from the same samples as in (c). All lanes
have positive, appropriately sized amplicons (140 bp) for 18s rRNA.
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Page 6 of 17Table 1 Primers used for PCR amplification analysis
Primer name Sequence FIV genomic position * Assay
feline GAPDH for 5’ AAA TTC CAC GGC ACA GTC AAG NA Feline GAPDH QT PCR
feline GAPDH rev 5’ TGA TGG GCT TTC CAT TGA TGA NA Feline GAPDH QT PCR
18s rRNA for 5’ GTA ACC CGT TGA ACC CCA TT NA Feline 18s rRNA
18s rRNA rev 5’ CCA TCC AAT CGG TAG TAG CG NA Feline 18s rRNA
FIV QT gag for 5’ TAG CCC TTG ACC CAA AAA TG 1067 FIVgag QT PCR
FIV QT gag rev 5’ ATT GGC CGA AAA AGC TGT AA 1167 FIVgag QT PCR
FIV Gag leader for 5’ GTT GGC GCCCGA ACA GGG 354 FIV gag sequencing
Gag circle rev 5’ GTA GAT GGT CTG GTG TCT AAT CCC A 989 FIV gag sequencing
FIV U5 rev 5’ TGC GAA GTC TTC GGC CCG GAC TCC G 338 FIV LTR sequencing
FIV env for 5’ TGG GAG TCC TCT GAC CGA GA 9043 FIV LTR sequencing + CJ A and B
FIV gag circle rev3 5’ GGT TTC ACT TTC CTA GCC TGC TC 403 CJ B
FIV gag rev 5’ TGA GTC AGC CCT ATC CCC ATT A 1345 CJ A
FIV u5 for 5’ CCT GTC GTG TAT CTG TGT AAT CTT TTC TAA C 290 CJ C
FIV u3 rev 5’ TGG AAC AAA ATC TAC GTC ATC GG 155 CJ C
QT PCR = real time PCR; CJ = circle junctions PCR; NA = not applicable
*5 ’ position of FIV primer
U3   R   U5    U3   R  U5 
GTTGGCGC AC  TGGGAAGATTGGGATCCTGATGG… 
U5  gag 
leader 
env  U3 
TGGGAAGATTGGGATCCTGATGG… 
number of clones 
with same sequence 
4* 
AC 
TGGGAAGATTGGGATCCTGATGG… 
 [Δ10 NT of  U3]GGGATCCTGATGG… 
1# 
1# 
…AAGACTTCGCA 
TGG        [Δ 122 NT of  U3] …                             
1+ 
1+ 
GT 
GT 
GT 
…AAGACTTCGCA 
…AAGACTTCGCA 
…AAGACTTCGCA 
…AAGACTTCGCA  GT 
CJ primer set C 
a 
b 
U3   R  U5   U3   R  U5 
Figure 5 Cloned viral 2-LTR circle junction sequences. PBMCs were isolated from FIV-infected cats 6 weeks (184) and 12 weeks (165) PI and
cultured ex vivo. DNA was isolated from ex vivo-cultured cells and 2-LTR CJ PCR was performed (CJ primer set C). 2-LTR CJ PCR products were
cloned and sequenced from cat 184 PBMCs incubated ex vivo for 3 days (*) and from cat 165 PBMCs incubated 4 (#) and 6 days (+). Circled
nucleotides represent the invariant CA and TG dinucleotides within the U5 and U3 regions, respectively, while the underlined nucleotides
represent a portion of the primer binding site within the gag leader.
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tides) and env open reading frames (0-2 nucleotides) at
the unique LTR-LTR circle junction. Six of the clones
contained intact U3 regions, while two demonstrated
variable blocks of deleted nucleotides from U3.
Ex vivo cultivation of CD4+ T cells harvested from cats
during chronic FIV infection results in transcriptional
activation and the production of infectious virus
To determine if viral transcription in latently infected
CD4+ T cells isolated from chronically infected cats
could be reactivated, we performed ex vivo culture
experiments with magnetic column-isolated CD4+ T
cells. At 124 to 126 weeks PI, blood was harvested from
the 4 FIV-infected cats (165, 184, 186 and 187) and an
uninfected control cat (183). Genomic DNA prepara-
tions from freshly isolated CD4+ T cells were tested for
FIV gag sequences using real-time PCR. FIV gag PCR
amplicons were detected in cells freshly isolated from
the FIV-infected cats (data not shown) although 2-LTR
CJ real-time PCR analysis performed on the same DNA
samples failed to detect amplicons (Figure 6e). Primer
concatemers are evident in lanes 4-8 and 10 at approxi-
mately 100-150 nucleotides, primer concatemers tend to
form stochastically in the absence of target template or
when the template is limiting. Viral gag RNA was not
detected by real-time RT-PCR using the same freshly
isolated CD4+ T cells from any cat (data not shown).
Although these findings are consistent with viral latency
in peripheral CD4+ T cells, due to the inherent limita-
tions in the sensitivity of any test, we cannot absolutely
rule out the possibility that low level viral transcription
is ongoing in these cells.
CD4+ T cells from FIV-infected and uninfected cats
were cultured with ConA and PMA mitogens for 3
(184, 187, 186) or 14 days (165, 183) as described above.
Both viral gag DNA and RNA were detected in samples
obtained from FIV-infected cat 165 by real-time PCR
and appropriately sized amplicons were evident on agar-
ose gel electrophoresis (Figure 6a). Circle junction LTR
DNA was not detected at this time point (data not
shown). The cultured CD4+ T cells were subsequently
co-cultured with an equal number of uninfected feline
CD4+ T cells or PBMCs for 5 (187, 184), 6 (165) or 10
(186) additional days. Genomic DNA samples prepared
from cat 165 ex vivo-cultured CD4+ T cells co-cultured
with uninfected PBMCs were subsequently shown to be
positive for CJ DNA (CJ primer set B) while cat 165
CD4+ T cells co-cultured with uninfected CD4+ T cells
were negative for CJ DNA (Figure 6c). 2-LTR CJ PCR
assays (CJ primer set C) performed with DNA isolated
from CD4+ T cells from FIV-infected cats co-cultured
with uninfected feline PBMCs demonstrated appropri-
ately sized amplicons (Figure 6e) consistent with a
productive viral infection (mean real-time PCR CT
values for lanes 1, 7-10, respectively: 29.9, 36.9, 37.1,
37.2 and 33.9). In addition, magnetic column freshly iso-
lated CD4+ T cells (126 weeks PI) from FIV-infected cat
187 were sorted by flow cytometry in the presence of
the CD4 antigen and absence of CD14 antigen. Sorted
CD4+ T cells, determined to be 99.6% pure, were cul-
tured ex vivo for 2 days followed by co-culture with SPF
feline PBMCs for 14 days. Consistent with a productive
infection, DNA isolated from the ex vivo-cultured cells
were positive for 2 LTR circle junctions by real-time
PCR (data not shown).
FIV LTR and gag sequences are relatively stable during
chronic infection
FIV sequence variation was examined in chronically
infected cats through the analysis of viral LTR, the gag
leader sequence and the 5’ terminus (361 nt) of gag
(matrix), as shown in Figure 7. This sequenced region
captures the encapsidation determinants in addition to
intervening sequences of unknown relevance. In HIV,
insertion and deletion mutations have been identified
within the gag leader sequence at or near the primer
binding site in both in vivo derived samples and in vitro
passaged virus [36,37]. A G to A mutation (single
nucleotide polymorphism; SNP) was identified at posi-
tion 93 of the viral genome in samples isolated from cat
187 at both 26 weeks and 57 weeks, relative to inoculat-
ing virus sequence. A distinct C to A SNP was detected
in samples isolated from cat 186 at 57 weeks at position
102. No LTR sequence changes were identified in sam-
ples isolated from cats 165 or 184 at any time point (4
samples analyzed for cat 165 and three samples for cat
184). In order to address promoter functionality, the
entire LTR of the inoculating virus was cloned and uti-
lized in the construction of an FIV LTR-b galactosidase
reporter plasmid (pBlue TOPO, Invitrogen). In addition,
this reporter plasmid was mutated to reflect point muta-
tions observed at positions 93 and 102 in U3 of FIV
LTR sequences from cats 186 and 187. The FIV promo-
ter demonstrated strong basal activity relative to nega-
tive controls based on b galactosidase expression when
transfected into human fetal kidney (293T) and feline
kidney cells (CRFK, Figure 8). For selected pair wise
comparisons in both the feline and human cell lines, the
point mutation at position 102 (C to A) resulted in
basal promoter expression levels comparable to the con-
sensus FIV LTR, but the mutation at position 93 (G to
A) abrogated basal FIV promoter expression to the level
of the negative controls. Interestingly, the mutation at
position 93 resides within the AP-1 transcription factor
binding site, which may explain the observed decrease
in promoter function. For each cell line, these experi-
ments were repeated 3 times with similar results.
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Figure 6 In vitro viral rescue assay in CD4+ T cells isolated by magnetic column at 126 weeks PI. FIV gag PCR products were present in
samples from FIV-infected cat (165) vDNA (lane 3) and vRNA (lane 4) (a). Amplicons were not identified in RT- samples (lane 5, cat 165 cDNA), or in
samples from the uninfected control cat (cat 183, DNA and cDNA, lanes 6 and 7 respectively). Positive [pDNA (plasmid), lane 2] and negative controls
(water template, lane 1) were appropriate. Appropriate-sized amplicons were generated with the feline GAPDH primer set (b) from the same samples
as in (a). CD4+ T cells derived from cat 165 were cultured ex vivo for 14 days and subsequently co-cultured for 6 days with SPF CD4+ T cells (lane 3,
negative) or PBMCs (lane 4, positive) and evaluated for FIV circle junctions (primer set B) (c). Positive (pDNA, lane 1) and negative controls (water
template, lane 2) were appropriate. Appropriate-sized amplicons (arrowhead) were generated for 18s rRNA gene (d) from the same samples as in (c).
Co-culture of latently infected CD4+ T cells with uninfected feline PBMCs results in detectable 2 LTR circle junction amplicons (e). Freshly isolatedC D 4
+ T cells derived from FIV-infected cats 165, 184, 187 and 186 (day 0, lanes 3-6, respectively) were cultured ex vivo for 14 days (165) or 3 days (184, 187
and 186) and subsequently co-cultured for 6 (165), 5 (187 and 184) or 10 (186) additional days with FIV-negative PBMCs (lanes 7-10, respectively).
Samples derived from cat 186 PBMCs cultured ex vivo for 13 days served as the positive control (lane 1) while water template served as the negative
control (lane 2). Expected PCR amplicons of 250 bp were generated with 2 LTR circle junction primer set C in lanes 1 (positive control) and 7-10
(arrowhead). Appropriate-sized amplicons (arrowhead) were generated for 18s rRNA gene (f) from the same samples as in (e).
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inoculating virus and viral sequences isolated from
infected cats at any time point within the gag leader/gag
open reading frame (2, 12, 26, 51, 57 and 62 weeks post
infection). In summary, only two SNP mutations were
identified in this set of viral sequences isolated from in
vivo infected PBMCs. PBMCs harvested from two FIV-
infected cats (cat 165 and 184) demonstrated viral
sequences identical to the inoculating virus throughout
the analyzed region (Figure 7). These data are suppor-
tive of minimal virus replication within PBMCs.
Discussion
A previous study described a state of FIV latency in
PBMCs in which plasma vRNA was undetectable by
quantitative RT-PCR in asymptomatic cats chronically
infected with FIV [38]. In another study, a model of FIV
latency was produced in cats by mucosal administration
of low-dose cell-associated FIV [39]. FIV establishes
latency in cell lines in vitro [30,40]. Our study, however,
is the first comprehensive report of FIV cellular latency
in peripheral blood CD4+CD25+ and CD4+CD25- T
cells as demonstrated by real-time PCR/RT-PCR, circle
junction PCR analyses and sequencing of the LTR and
gag gene of the integrated FIV provirus over an
extended period of time and chronic infection. Notably,
although FIV appears to be transcriptionally silent in
both resting and activated CD4+ T cells, HIV-1 is
t h o u g h tt ob es i l e n to n l yi nr e s t i n gTc e l l s[ 4 1 ] ,
suggesting that some differences exist between FIV and
HIV-1 in viral-host cell interactions.
Although the identification of circle junction viral
DNA products has been utilized as an indicator of
ongoing viral replication in HIV-1 infected individuals,
this method is controversial since the circles are stable
dead end products that do not support viral replication
[32,35]. In fact, HIV-infected elite suppressors, relative
to HIV-infected patients on and off ART, have been
shown to harbor low levels of integrated HIV DNA and
high levels of 2-LTR circles in PBMCs [42]. In our
study, 2-LTR CJ were not detectable from uncultured
magnetic column-isolated CD4+ T cells; however, ex
vivo activation of these sorted cells resulted in detectable
2 LTR CJ, consistent with the concept of a productive
viral infection. Sequence analysis of FIV 2 LTR CJ
amplicons has not been previously reported, and our
analysis demonstrated a variety of inserted nucleotides
and deletions at the LTR-LTR circle junction. The most
common sequence identified (4 of 8 sequenced clones)
contained 6 nucleotides of the primer binding site as
well as the dinucleotides flanking the U5 and U3
regions. Similar fragments of the primer binding site
sequence have been amplified from 2 LTR CJ products
cloned from PBMCs of HIV-1 infected individuals [43].
T h em o s tc o m m o nC Js e q u e n c ec l o n e df r o mH I V - 1
infected individuals was 5’ GTAC [43,44], which repre-
sented only 1 of 8 sequences in our data set. Removal of
these 4 nucleotides, GTAC, at the center of the circle
187 
165 
184 
186 
Inoculating virus 
ATG  gag (p15/MA) 
U3 R  U5 
0        207 287  354               632                        993 
5’ LTR 
cat no.     2 weeks PI       26 weeks PI  57 weeks PI              62 weeks PI
  
*  * 
* 
G93A 
C102A 
51 weeks PI  12 weeks PI 
PBS 
SD 
Figure 7 Stability of the LTR/gag sequence in the integrated FIV provirus during the course of infection. The subgenomic region of the
inoculating FIV provirus, shown at the top of the figure, was PCR-amplified from PBMCs of infected cats and analyzed by DNA sequencing.
Relative nucleotide positions within the amplified sequence are indicated with PBS denoting the primer binding sequence, SD denoting the
splice donor, and ATG marking the start of gag translation. Viral sequences derived from PBMCs isolated at different time points from the four
different FIV-infected cats are depicted schematically.
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Page 10 of 17junction unambiguously generates the sequences of the
LTRs found in integrated proviral DNA [44]. Therefore,
integration of retroviruses involves removal of the dinu-
cleotides flanking U5 and U3 from each end of the lin-
ear viral DNA [44-46]. Two of our clones demonstrated
deletions in the U3 region (10 and 122 nucleotides),
which were also identified in samples obtained from
HIV-1 infected humans, 8 and 110 nucleotide deletions
of HIV U3. Indeed, a large proportion of circular HIV-1
DNA molecules in infected cells demonstrate deletions
or other mutations at the circle junction [44]. It is possi-
ble that 2-LTR circle junction products are preferentially
derived from defective linear intermediates. Alterna-
tively, a large proportion of the linear, integrative form
of lentiviral DNA has incorrect termini, rendering it
unable to integrate [44].
The viral LTR and gag leader/gag matrix regions
derived from freshly isolated PBMCs demonstrated
minimal to no sequence variation over time. Although
limiting dilution single genome amplification might
reveal other, undetected, changes within the sequenced
locus, it is unlikely that frequent or large mutations
would remain undetected by the sequencing techniques
utilized in this study. FIV encapsidation determinants
are bipartite, involving a contiguous region of R, U5 and
the proximal aspect of the gag leader sequence in addi-
tion to the first 230 nucleotides of the gag matrix gene
[47-50]. Interestingly, and in contrast to what is known
for other mammalian retroviruses, the region between
the major splice donor and gag gene has been demon-
strated to be dispensable for FIV encapsidation [49,50].
Therefore, a genetic locus within the 3’ aspect of the
FIV gag leader region is not constrained by encapsida-
tion sequence requirements and has no gene coding
function. FIV genetic variation in this region over time
therefore seems plausible. The lack of sequence varia-
tion in the gag leader/matrix gene between the inoculat-
ing virus and viral isolates obtained from chronically
infected cats suggests that genetic constraints, in addi-
tion to the encapsidation determinants and tRNA
treatment
CMV no tx empty FIV G93A C102A
B
e
t
a
 
g
a
l
a
c
t
o
s
i
d
a
s
e
 
O
D
0.0
0.5
1.0
1.5
2.0
2.5
3.0
a 
treatment
CMV no tx empty FIV G93A C102A
B
e
t
a
 
g
a
l
a
c
t
o
s
i
d
a
s
e
 
O
D
0.0
0.5
1.0
1.5
2.0
2.5
3.0
b 
TGGGAAGATTATTGGGATCCTGATGGAATAGAAAAGATGTTAATGGACTAAGAGCCTTGCAATATTAAGTAATAA 
 
TGGAAACAGCTGATTATGACTCAGAGCTAGCAGCTGCTTAACCGCAAAACCACATCCTATGTAAAGCTTGCCGA 
 
 
 
TGACGTAGATTTTGTTCCATTGTAAGACTATATAATCAGTGCTTTGGAAAGCTTCGAG 
 
AP-4 C/EBP  AP-4 
ATF 
AP-1 
C102A  G93A 
c 
* 
* 
NS 
NS 
* 
* 
Figure 8 Point mutations in the FIV-C promoter showing either no effect or abrogating promoter function in an in vitro reporter
assay.I na nin vitro FIV promoter-b galactosidase reporter system, the promoter of the inoculating virus and the C102A mutated promoter
demonstrated strong basal promoter function in (a) feline CRFK and (b) human 293T cells relative to negative controls (no transfection and a
promoterless b galactosidase plasmid- no tx and empty, respectively). Cells transfected with a CMV-b galactosidase (CMV) plasmid served as a
positive control. Statistical significance is denoted by an asterisk for selected pair wise comparisons (*, p < .05) whereas error bars denote
standard deviation. However, cells transfected with the G93A promoter mutant failed to demonstrate a basal promoter function above the
negative controls (not significant, NS). The sequence of the promoter in the U3 region of the inoculating FIV-C virus (c) demonstrates multiple
cis-acting transcriptional elements (light grey text). The G93A mutation lies within the putative AP-1 binding site whereas C102A is located
between binding sites (white arrows).
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Page 11 of 17primer binding site, may be present in this region. We
found the FIV promoter derived from the inoculating
virus to be functional in both feline and human cell
lines. Two U3 promoter mutations were identified in
two of the cats, at position 93 and 102. Although the
mutation at position 102 had no apparent effect on FIV
promoter function, the mutation at position 93 abro-
gated basal promoter expression. Nucleotide position 93
lies within an AP-1 transcription factor binding site
while locus 102 is between known binding sites.
Although previous studies have demonstrated that dele-
tion of the FIV AP-1 site had negligible effects on virus
expression, deletion of multiple cis-acting transcriptional
elements (including AP-1) has been demonstrated to
attenuate FIV [51]. These findings suggest that at least
in one cat (187), lentiviral transcriptional attenuation
and latency may be associated with mutations within
the U3 promoter.
The intermittently detectable vRNA in the PBMC
samples may be due to the presence of vRNA-positive
monocytic cells within the PBMC samples. However,
FIV is capable of infecting other leukocyte subtypes,
such as B lymphocytes and CD8+ T cells [1,3,52-54],
which could be productively infected and contributing
to these intermittently vRNA positive PBMC samples.
Viral antigen has been immunohistochemically localized
in feline tissues in situ within T lymphocytes, macro-
phages and dendritic cells [55]. In a transmucosal FIV
infection model, evidence suggests that within hours of
exposure, mucosal dendritic cells and CD3+ T cells are
infected and rapidly traffic to systemic lymphoid tissues
[56]. Lentivirus-infected monocytes are rarely detected
in the blood of animals or people infected with immu-
nodeficiency-inducing lentiviruses, yet tissue macro-
phages are thought to be a significant reservoir of virus-
infected cells in vivo [57]. English et al. detected FIV
provirus in uncultured monocyte-enriched PBMCs in
only 1 in 10 asymptomatic cats infected with FIV-
NCSU1, a clade A strain [54]. However, some strains of
virus are apparently monocytotropic in vivo,a n dt h i s
property may correlate with virulence [57]. Importantly,
data from this current study provide additional support
for FIV-C-Pgmr as a monocytotropic strain.
Although low copy numbers of vRNA were intermit-
tently identified in freshly isolated PBMCs and mono-
cytes from FIV-infected cats, no vRNA was detected in
plasma by sensitive real-time PCR assays at any time
point after 44 weeks. This finding could be explained in
several ways. It may be due to an insufficient sensitivity
of the real-time RT-PCR assay used in this study. The
threshold of detection for the vRNA assay was approxi-
mately 80 copies vRNA per ml of plasma; therefore, low
levels of viremia could exist that remain undetectable
through the assays employed in this study. The
chronically infected cats may be analogous to HIV-1
infected patients on antiretroviral therapy, thought to
have an occult viremia of between 1 and 50 copies of
vRNA per ml of plasma that is not detectable by stan-
dard real-time RT-PCR assays [27,58]. Alternatively, rare
copies of gag vRNA detected within the freshly isolated
monocytes and PBMCs may not be translated into viral
proteins and/or assembled into releasable virions due to
an unidentified post-transcriptional blockade mechanism
(e.g. inhibition of viral translation, assembly or release).
For HIV-1 infected individuals on ART, cells harbor-
ing defective integrated proviruses are found at frequen-
cies 100-600-fold greater than cells with replication
competent genomes [59,60]. Defective genomes within
PBMCs and CD4+ T cells isolated from chronically
infected cats were not investigated in this study. How-
ever, productive viral infection through ex vivo culture
and activation of latently infected cells from chronically
infected cats were demonstrated by multiple approaches.
These results strongly suggest that at least a portion of
the latently infected PBMCs harbor integrated replica-
tion competent FIV proviruses that are capable of pro-
ducing infectious virions through mechanism(s) of
transcriptional activation.
Conclusions
Through the isolation of latently-infected leukocyte sub-
types and access to tissues (via both surgical biopsy and
necropsy), chronic FIV infection of cats may provide a
useful animal model for the elucidation of in vivo
mechanisms of lentiviral latency. As such, the FIV-
infected cat in the asymptomatic phase is proposed as a
model of peripheral CD4+ T cell latency. Importantly,
mechanisms of transcriptional repression identified in
this animal model of lentiviral latency may reveal analo-
gous mechanisms of persistence in ART-treated HIV-
infected human patients.
Methods
Animals and virus
Six FIV SPF kittens were obtained from the breeding
colony of the Feline Nutrition Laboratory, University
California at Davis (UC Davis). The kittens ranged in
age from 4 to 5 months and were housed in the Feline
Research Laboratory (FRL) of the Center for Companion
Animal Health (CCAH), UC Davis. Husbandry care was
provided by staff of the CCAH under the supervision of
the Center for Laboratory Animal Services, UC Davis.
The study protocol was approved by the UC Davis Insti-
tutional Animal Care and Use Committee.
A single 5 1/2 month old male kitten (165) was inocu-
lated with one ml FIV-C-Pgmr viral inoculum (~10
5
TCID50) in the musculature of the left caudal thigh. The
FIV-C-Pgmr isolate was provided by Drs. E. Hoover and
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cal signs of FIV-associated immune deficiency weekly
and peripheral blood was assayed for complete blood
count, FIV antibody by ELISA (SNAP FIV/FeLV Combo
test, IDEXX Laboratories, Westbrook, Maine), FIV p24
antigen by ELISA, and changes in CD4+ and CD8+ fre-
quency by flow cytometry every two weeks. Viral loads
in blood were tested by real-time RT-PCR assays mea-
suring copy numbers of cellular FIV vDNA and plasma
FIV RNA. Six weeks post-inoculation, plasma was har-
vested from the FIV-infected kitten, clarified, and used
to infect SPF feline PBMCs in vitro. Eleven days post-
infection, clarified supernatant from plasma-inoculated
PBMC cultures was determined to contain 7.5 × 10
8
viral RNA copies/ml by real-time PCR. Three 4-5
month old kittens (cats 184, 186 and 187, all males)
were next inoculated with culture supernatant (1 ml; 7.5
×1 0
7 viral RNA copies, 1:10 dilution of virus stock in
sterile media) in the left caudal thigh musculature, as
described above. Two control kittens (183 and 185)
were mock-inoculated with 1 ml of sterile culture
media. Kittens were housed, monitored for clinical ill-
ness by physical examinations, and sampled for blood by
venipuncture every two to four weeks up to 112 weeks
after inoculation.
CD4+ lymphocyte and monocyte purification
Feline whole blood was collected by jugular venipunc-
ture and PBMCs were harvested by density gradient
centrifugation through Ficoll-Hypaque (Sigma, St. Louis,
Mo.). Isolated PBMCs were resuspended and separated
through a combination of magnetic-bead columns (Mil-
tenyi Biotec Inc., Auburn, CA) and flow cytometric cell
sorting. Briefly, cells were enumerated using an auto-
mated cell counter (Coulter A
CT diff, Beckman Coulter)
and approximately 2 x10
7 were used for primary anti-
body (Ab) binding. PBMCs were initially depleted of
monocytes, B cells and granulocytes via an LD column
(MACS Separation Columns, Miltenyi Biotec Inc.,
Auburn, CA) and a cocktail of mouse anti-feline antibo-
dies: anti-CD11b (clone CA16.3E10-IgG1), anti-CD8a
(clone FE1.10E9-IgG1), anti-CD21 (clone CA2.1D6-
IgG1), (antibodies provided by Peter Moore, UC Davis)
and goat-anti mouse IgG-microbeads (Miltenyi Biotec)
according to the manufacturers’ instructions. The flow-
through cell fraction was treated with mouse anti-feline
CD25 monoclonal antibody (clone 9F23; gift of Koichi
Ohno, University of Tokyo) and applied onto a MS col-
umn (MACS Separation Columns, Miltenyi Biotec Inc)
along with goat-anti mouse IgG-microbeads (Miltenyi
Biotec). Column-sorted cells were treated with a block-
ing antibody (1 mg/ml, CA2.1D6, FHCRC Biologics).
Anti CD4-FITC antibodies (FE1.7B12, P. Moore, UC
Davis) were used to label both the cells retained by the
MS column and the flow-through fractions. Monocytes
were isolated from the cell fraction retained from the
LD column. A conjugated secondary antibody was
added to these retained cells (mouse anti-human CD-
14-ALEXA Fluor 647; AbD Serotec). PBMCs labeled
with ALEXA and FITC-conjugated secondary antibodies
were secondarily sorted and enumerated by flow cyto-
metry (MoFlo Cell Sorter, Cytomation Inc., Fort Collins,
CO) at the UC Davis Flow Cytometry Shared Resource.
Cells were gated on size (forward scatter/sidescatter),
live cells (propidium iodide exclusion), single cells (pulse
width) and fluorochrome expression (ALEXA or FITC).
Typical yields for monocytes, CD4+CD25+ and CD4
+CD25-, were 2.5 × 10
5 cells, 2.4 × 10
5 and 1.7 × 10
6,
respectively. The purity of all three sorted cell popula-
tions was determined to be approximately 99%, as deter-
mined by CD14 or CD4 expression (monocytes and
CD4+ T lymphocytes, respectively).
For virus rescue assays from latently infected CD4+ T
cells, a modified protocol was followed for isolating
viable CD4+ T cells. In this modified protocol, PBMCs
from both FIV-infected and uninfected animals were
depleted using an LD column (Miltenyi Biotec) as
described above. The flow-through cell fraction was
treated with anti CD4 antibodies (FE1.7B12, P. Moore,
UC Davis) along with goat-anti mouse IgG-microbeads
(Miltenyi Biotec). Labeled cells were then applied to a
second LD column and retained cells were immediately
cultured ex vivo. Typical yields of CD4+ T cells were 6
×1 0
6 cells while cell purity was determined to be 97%
CD4+ T cells, with approximately 0.1% contaminating
CD14+ cells and less than 3% CD4- CD14- cells.
Hematologic assessment of cats
Complete blood cell counts were performed on Coulter
counter (Coulter ACT diff2, Beckman Coulter, Fuller-
ton, CA) and differentials were performed on cytologic
smears of whole blood. PBMCs isolated by Ficoll Hypa-
que gradient centrifugation were phenotyped for CD4+
and CD8+ lymphocyte frequency by flow cytometry
using anti-feline CD4 (FE1.7B12) and anti-feline CD8a
(FE1.10E9). Secondary antibody, fluorescein-conjugated
horse anti-mouse IgG (Vector Laboratories, Inc.,
Burlingame, CA) was utilized for detection. Samples
were analyzed on a FACScan instrument (Becton Dick-
inson, San Jose, CA) using FloJo v8.6.3 flow cytometry
analysis software (Tree Star, Ashland, OR). Absolute
CD4+ and CD8+ cell counts in blood were derived from
absolute lymphocyte counts and subset frequencies
determined by flow cytometry.
Real-time PCR assays
Cell-associated RNA and DNA were co-isolated utilizing
a commercial kit (AllPrep DNA/RNA Mini Kit, Qiagen,
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vRNA was isolated using a different commercial kit
(QIAamp Viral RNA Mini Kit, Qiagen) according to
manufacturers’ instructions. DNase treatment of isolated
RNA was accomplished with TURBO DNase (Ambion,
A u s t i n ,T X ) .R N Aw a sr e v e r s et r a n s c r i b e di n t oc D N A
with the OriGene 1
st Strand cDNA Synthesis System for
Quantitative RT-PCR (Origene, Rockville, MD). A con-
trol reaction excluding reverse transcriptase was
included for each sample. Real-time PCR assays were
performed in triplicate with Real Mastermix SYBR Rox
(5 Prime, Gaithersburg, MD) on an Applied Biosystems
7300 Real-time PCR System and subsequently analyzed
with the 7300 system software (Applied Biosystems,
C a r l s b a d ,C A ) .R e a l - t i m ePCR and RT-PCR assays to
quantify viral nucleic acids used primers based on FIV-
C-Pgmr gag sequence (Table 1). The PCR annealing
temperature was optimized using a gradient PCR system
(Eppendorf Mastercycler). Quantification of plasma FIV
RNA copy number was based on a standard curve gen-
erated from viral transcripts prepared by in vitro tran-
scription of a plasmid (pCR2.1, Invitrogen) containing a
101 nucleotide-long FIV-C-Pgmr gag amplicon.
For assay of cell- associated vDNA and vRNA, real-
time PCR assays of feline GAPDH were included to nor-
malize input nucleic acid concentration. Because there
are two allelic copies of the housekeeping gene GAPDH
per cellular genome [61], viral gag DNA copy number
was normalized to 1 × 10
6 copies of GAPDH (deter-
mined from the same sample) which was expressed as
DNA copy number per 5 × 10
5 cells (copies GAPDH/2
= number of cells). For RT-PCR, a similarly derived
standard curve specific for feline GAPDH transcripts
was utilized. Viral RNA copy number was normalized to
1×1 0
6 copies cellular GAPDH RNA, performed on the
same RNA sample in parallel. The cycling conditions for
GAPDH assay were as follows: 50°C for 2 minutes, 95°C
for 2 minutes followed by 40 cycles of 95°C for 15 sec
and 60°C for 30 sec and a final elongation step at 72°C
for 5 minutes. The cycling conditions for the FIV gag
assay were as follows: 50°C for 2 minutes, 95°C for 2
minutes followed by 40 cycles of 95°C for 15 sec, 58°C
for 30 sec, 68°C for 30 sec and a final elongation step at
72°C for 5 minutes. The cycling conditions for 2 LTR
circle junction assay were as follows: 50°C for 2 minutes,
95°C for 2 minutes followed by 40 cycles of 95°C for 15
sec, 56°C for 30 sec and 72°C for 30 seconds. All real-
time PCR assays were followed with a dissociation step
(melt curve).
Standard PCR assays
Standard PCR was performed with Platinum Taq DNA
polymerase (Invitrogen) on an Eppendorf Mastercycler
(Eppendorf). The cycling conditions for PCR
amplification of LTR sequences, gag leader/gag orf
sequences, and feline 18s ribosomal RNA were as fol-
lows: 95°C for 2 minutes followed by 40 cycles of 95°C
for 15 sec, 56°C for 30 sec, 72°C for 30 sec and a final
elongation step at 72°C for 5 minutes. Circle junction
PCR (primer sets A and B) was performed using the fol-
lowing reaction conditions: 95°C for 5 minutes followed
by 30 cycles of 95°C for 30 sec, 58°C for 60 sec, 72°C
for 120 sec and a final elongation step at 72°C for 5
minutes. PCR products were analyzed on 1-2% agarose
gels, stained with ethidium bromide for visualization.
Primers for PCR
Primers were designed based on GenBank sequences and
sequences derived from the FIV-C-Pgmr viral inoculum.
Real-time PCR primers (FIV gag and feline GAPDH) were
optimized using primer design software (Integrated DNA
technologies Inc. OligoAnalyzer- http://www.idtdna.com/
analyzer/Applications/OligoAnalyzer/) and were synthe-
sized by a commercial vendor (IDT, Coralville, IA). Two
LTR CJ primers were based on cloned sequences. Primer
pairs are further described by name, sequence, FIV geno-
mic location and assay type in Table 1. Real-time PCR pri-
mers were utilized as follows: feline GAPDH (Feline
GAPDH for and Feline GAPDH rev), 2-LTR circle junction/CJ
PCR C (FIV U5 for and FIV U3 rev), and FIV gag (FIV QT gag
for and FIV QT gag rev). Standard PCR primers were utilized
as follows: circle junction PCR A (FIV env for and FIV gag
rev), circle junction PCR B (FIV env for and FIV gag circle
rev3), LTR (FIV env for and FIV U5 rev), gag leader/gag orf
(FIVGag leader for and Gagcircle rev) and Feline 18s rRNA (18s
rRNA for and 18s rRNA rev).
Nucleotide sequencing and analysis
A proviral subgenomic fragment containing the long term-
inal repeat (LTR) through the first 637 nucleotides of the
FIV leader and gag gene (nt 1-993) were PCR amplified
from genomic DNA isolated from PBMCs of each FIV-
infected cat and then sequenced. Viral sequences were
determined for different time points including acute infec-
tion (2 weeks PI), early chronic infection (21-26 weeks PI)
and chronic infection (51-62 weeks PI). Nucleotide
sequence of the FIV-C-Pgmr virus inoculum was deter-
mined from cDNA generated from inoculum viral RNA.
Nucleotide sequence of inoculum cDNA was based on
molecularly cloned PCR products (pCR2.1, TA cloning
s y s t e m ,I n v i t r o g e n ,C a r l s b a d ,C A ) .N u c l e o t i d es e q u e n c e s
were aligned and compared using the AlignX function of
Vector NTI software (Invitrogen, Carlsbad, CA).
Virus rescue assays
PBMCs were isolated from blood samples by Ficoll-
Hypaque (Sigma-Aldrich) density centrifugation for both
FIV-infected and uninfected cats at 50 weeks post
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tocols [34] with the modification that cells were also
cultured with 0.1 μg PMA/ml (Sigma-Aldrich) in addi-
tion to 5 μg Con A (ThermoFisher Scientific) per ml for
activation of viral gene expression. PBMC cultures were
provided with fresh media on day 8. PBMCs harvested
on day 10 were processed for genomic DNA to test for
viral DNA loads by real-time PCR assays based on gag
sequence. Similarly, PBMC culture supernatants were
collected on day 10 to assay for viral RNA by real-time
RT-PCR and to assess for infectivity on virus-naïve SPF
feline PBMCs cultured by standard protocols [34]. Mag-
netic column-Isolated viable CD4+T cells were cultured
ex vivo as described for PBMCs at a concentration of 2
million cells/ml media. The media were exchanged for
fresh media every 5 days. On days 3 or 14 of culture,
CD4+ T cells were co-cultured with FIV-negative feline
PBMCs or CD4+ T cells for 5, 6 or 10 additional days.
Ex vivo-cultured cells were processed for nucleic acids
and assayed by PCR as described above for PBMCs.
For virus infectivity assays, approximately 9 × 10
6 SPF
PBMC cultures were inoculated with 0.5 mL of clarified
supernatant harvested from PBMC cultures derived
from FIV-infected or uninfected (control) cats. On day 7
of culture, cells were harvested and processed for RNA
and DNA using a commercial kit (Qiagen DNA/RNA
minikit, Qiagen). PBMC culture supernatants were also
harvested and tested for vRNA using real-time RT-PCR
as described in the Methods section for PCR assays.
FIV promoter-reporter assay
DNA was isolated from PBMCs infected with the inoculat-
ing FIV-C-Pgmr (QIAamp DNA Minikit, Qiagen). The
proviral LTR was amplified via PCR (FIV env for and FIV
U5 rev) and cloned into a b galactosidase expression plas-
mid (pLTR blue, derived from pBlue TOPO, Invitrogen).
The sequence of the proviral LTR was confirmed by
sequencing the insert. To replicate the two point muta-
tions identified in the FIV U3 promoter of cats 186 and
187, targeted point mutation of pLTR blue was performed
with a commercial mutatagensis kit (Quikchange Lighten-
ing Site-Directed Mutagenesis Kit, Agilent Technologies,
La Jolla, CA) according to the kit instructions, and using
primers designed on the manufacturer’s website http://
www.stratagene.com/qcprimerdesign. The resulting plas-
mids were sequenced and found to be identical to pLTR
blue, with the exception of a G to A substitution at posi-
tion 93 within U3 (pLTRG93A blue), or a C to A substitu-
tion at position 102 within U3 (pLTRC102A blue). CRFK
cells (ATCC, Manassas, VA), and 293T cells (courtesy of
Washington State University) were transfected with pLTR
blue, pLTRG93A blue, pLTRC102A blue, control plasmids,
or no plasmid (Lipofectamine 2000 Reagent, Invitrogen)
according to the Lipofectamine protocol. Control plasmids
consisted of a positive control plasmid with the CMV pro-
moter upstream of the b galactosidase gene (pcDNA
3.1D/V5-His/lacZ, Invitrogen) and a promoterless b galac-
tosidase plasmid (negative control). Transfected cells were
harvested 48 hours later and a b galactosidase assay was
performed in triplicate with cell lysates according to stan-
dard protocols [62]. Relative b galactosidase activity was
determined by a spectrophotometer; assays were repeated
three times.
Statistical analysis
Data are presented as the mean of three or more values
with the standard deviation displayed as error bars. An
analysis of variance was performed (ANOVA) on each
data set. Where global differences were identified, the
Tukey-Kramer Multiple Comparisons Test was utilized
for pair-wise comparisons of the mean responses
between treatment groups. Error bars denote standard
deviation. A P value < 0.05 was considered to be statisti-
cally significant. Statistics were performed with InStat
software (GraphPad Software Inc., La Jolla, CA).
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